Skip to main content

Table 1 Summary of TCGA and Mayo Clinic Studies

From: Drug discovery using clinical outcome-based Connectivity Mapping: application to ovarian cancer

  TCGA (n = 407) Mayo Clinic (N = 326)
Time to recurrence/Progression free survival
 Median TTR 15.3 (months) 13.0 (months)
 No recurrence/No progression 49.87 (%) 31.59 (%)
 Recurrence/Progression 48.40 (%) 67.79 (%)
Stage
 I 3.19 (%) 1.53 (%)
 II 4.17 (%) 3.06 (%)
 III or IV 92.13 (%) 95.39 (%)
Age
 Mean, [Q1, median, Q3] 59.8 [53, 60, 68] 58.3 [50, 55.5, 66.25]
Surgical debulking
 Optimal 65.11 (%) 73.92 (%)
 Sub-optimal 23.83 (%) 24.84 (%)